Myocardial distribution and biotransformation in vitro and in vivo of nicorandil in rats, with special reference to mitochondria

Journal of Cardiovascular Pharmacology

Volumn 33, Issue 1, 1999, Pages 163-168

  Sakai, Kazushige ^a   Tsuchiya, Yoko ^a   Kitajima, Shunichi ^a,b   Hamada, Hidemi ^a,b  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Panapharm Laboratories Co Ltd   (Japan)

Author keywords

Degradation; K(ATP) channels; Mitochondria; Oral nicorandil and rats; Subcellular distribution in hearts

Indexed keywords

N (2 HYDROXYETHYL)NICOTINAMIDE; NICORANDIL; NICOTINAMIDE DERIVATIVE; POTASSIUM CHANNEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; CELLULAR DISTRIBUTION; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TRANSFORMATION; ELECTRON MICROSCOPY; HEART MITOCHONDRION; HEART MUSCLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; BIOTRANSFORMATION; HUMANS; MALE; MITOCHONDRIA, HEART; MYOCARDIUM; NICORANDIL; POTASSIUM CHANNELS; PROTECTIVE AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SUBCELLULAR FRACTIONS; TISSUE DISTRIBUTION;

EID: 0032925283     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199901000-00025     Document Type: Article

References (27)

1. Sakai K. Nicorandil: animal pharmacology. Am J Cardiol 1989; 63:J2-10.
2. Kinoshita M, Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc Drugs Ther 1990;4:1075-88.
3. Krumenacker M, Roland E. Clinical profile of nicorandil: an overview of its hemodynamic properties and therapeutic efficacy. J Cardiovasc Pharmacol 1992;20:S93-102.
4. Gross GJ. The cardioprotective effects of nicorandil. Rev Contemp Pharmacother 1993;4:199-206.
5. Saito S, Mizumura T, Takayama T, et al. Antiischemic effects of nicorandil during coronary angioplasty in humans. Cardiovasc Drugs Ther 1995;9:257-63.
6. Kobayashi Y, Goto Y, Daikoku S, et al. Cardioprotective effect of intravenous nicorandil in patients with successful reperfusion for acute myocardial infarction. Jpn Circ J 1998;62:183-9.
7. + channel opener aprikalim (RP 52891) reduces experimental infarct size in dogs in the absence of haemodynamic changes. J Pharmacol Exp Ther 1991;259:961-7.
8. ATP channel as a receptor for potassium channel openers. J Biol Chem 1996;271:8796-9.
9. + channels. Circ Res 1997;81:1072-82.
10. + channel in the mitochondrial inner membrane. Nature 1991;352:244-7.
11. + channel from rat liver and beef heart mitochondria. J Biol Chem 1992;267:26062-9.
12. Sakai K, Moriyasu M, Kitajima S, Akima M, Kamachi S, Tanikawa M. Vascular levels and cGMP-increasing effects of nicorandil administered orally to rats. J Cardiovasc Pharmacol 1998;31: 595-600.
13. Sakai K, Akima M, Kamachi S, Moriyasu M, Kitajima S. Interrelationship of cardiovascular effects, plasma levels of nicorandil, and vascular cGMP formation in conscious rats. J Pharm Pharmacol 1998;50:661-6.
14. Hess B, Brand K. Methods for animal tissue and microorganisms. In: Bergmeyer HV, ed, Methods of enzymatic analysis. New York: Academic Press, 1974:399-409.
15. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193: 265-75.
16. Kingsley RE, Cole NL. Preparation of cultured mammalian cells for transmission and scanning electron microscopy using aclar film. J Electron Microsc Tech 1988;10:77-85.
17. Frydman A. Pharmacokinetic profile of nicorandil in humans: an overview. J Cardiovasc Pharmacol 1992;20:S34-44.
18. Taira N. Similarity and dissimilarity in the mode and mechanism of action between nicorandil and classical nitrates: an overview. J Cardiovasc Pharmacol 1987;10:S1-9.
19. Lenz T, Wagner G. Potential role of potassium channel openers for treatment of cardiovascular disease. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis, and management. New York: Raven Press, 1995:2953-68.
20. + channel openers in guinea-pig ventricular cells. Br J Pharmacol 1997;120:1568-74.
21. Sakai K, Saito K. Comparison of the potentiating effects of nicorandil and its denitrated metabolite (SG-86) on the adenosine-induced vasodepression in rats. Fund Clin Pharmacol 1998;12: 492-7.
22. + channels in cardiovascular medicine. Paris, France: Springer Verlag, 1993:95-106.
23. Rubino A, Burnstock G. Capsaicin-sensitive sensory-motor neurotransmission in the peripheral control of cardiovascular function. Cardiovasc Res 1996;31:469-79.
24. Mubagwa K, Mullane K, Flaming W. Role of adenosine in the heart and circulation. Cardiovasc Res 1996;32:797-813.
25. Saito K, Sakai K. Enhancement of the vasodepressor response to adenosine by nicorandil in rats: comparison with cromakalim. Fund Clin Pharmacol 1998;12:37-43.
26. Sakai K, Akima M, Saito K. Differential effects of nicorandil on the vasodepressor responses to vasoactive polypeptides administered intravenously to rats. J Pharm Pharmacol 1998;50:211-4.
27. ATP channels. Fund Clin Pharmacol 1998;12:143-51.